Keeping brain border immune cells active to improve spinal fluid flow in aging and Alzheimer’s
Long-lived Activation of Parenchymal Border Macrophages Using Immunocytokines to Address Aging- and Alzheimer’s Disease-associated Deficits in Cerebrospinal Fluid Dynamics
This project tries antibody-linked proteins that slowly release a brain immune factor to help clear waste from the brains of older adults and people with Alzheimer’s disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11326301 on NIH RePORTER |
What this research studies
The team is creating antibody–cytokine fusion proteins that hold a growth factor (M‑CSF) near parenchymal border macrophages so those immune cells stay active longer and help spinal fluid clear waste. Prior work showed that giving M‑CSF into the spine helped mice but wore off quickly, so these antibody fusions aim to form longer-lasting depots and could be given into the spine or through the bloodstream. Researchers will design and test these constructs in the lab and in animal models to see whether they improve cerebrospinal fluid flow and reduce harmful protein buildup linked to Alzheimer’s. This is an early proof‑of‑concept effort to show the approach can work before moving toward human testing.
Who could benefit from this research
Good fit: This work is most relevant to older adults and people diagnosed with Alzheimer’s disease—particularly those with suspected problems in cerebrospinal fluid clearance or amyloid-related pathology.
Not a fit: People without Alzheimer’s or age-related CSF clearance issues, or those who cannot receive intrathecal or antibody-based therapies, are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could help remove toxic proteins and improve brain waste clearance, which might slow cognitive decline in people with Alzheimer’s or age-related brain clearance problems.
How similar studies have performed: Animal studies showed intrathecal M‑CSF can improve CSF dynamics, but using long‑lasting antibody–cytokine fusions for this purpose is a novel and untested delivery approach in humans.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Tessier, Peter M — University of Michigan at Ann Arbor
- Study coordinator: Tessier, Peter M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.